Editor-in-Chief
Hatice Kübra Elçioğlu
Vice Editors
Levent Kabasakal
Esra Tatar
Online ISSN
2630-6344
Publisher
Marmara University
Frequency
Bimonthly (Six issues / year)
Abbreviation
J.Res.Pharm.
Former Name
Marmara Pharmaceutical Journal
Journal of Research in Pharmacy
2023 , Vol 27 , Issue 6
Potency of tamoxifen against clinical isolates of Candida resistant to itraconazole
1Department of Microbiology, College of Medicine, University of Karbala, Karbala, Iraq
DOI :
10.29228/jrp.546
Tamoxifen (TAM) has been shown to have an antifungal action along with its anticancer activity.
Various species of fungi have shown varying susceptibility to TAM. The antifungal activity of TAM was studied against
clinical pathogenic species of Candida that are resistant to itraconazole through using disk diffusion and dilution
methods. Of 50 isolates of Candida from women with vulvovaginal candidiasis, 15 isolates were resistant to itraconazole.
These isolates consisted of four isolates of C. albicans, ten isolates of C. glabrata and one isolate of C. utilis. All isolates
were inhibited by a high concentration of TAM (20 mg/ml). Candida albicans was affected by TAM at10 mg/ml (MIC,
5.5-7 mg/ml). High susceptibility with a low MIC value of TAM (3 mg/ml) was observed in Candida glabrata isolates.
Candida utilis was also found to be the isolate with the highest resistance to TAM (MIC, 15 mg/ml). In conclusion; TAM
is an effective agent against drug-resistant species of Candida in high concentrations. It was also demonstrated that
resistant isolates of C. glabrata are the most susceptible to TAM. High-dose of TAM is recommended for the treatment
of fungal infections caused by drug-resistant species of Candida. Further studies are needed in this concern.
Keywords :
Keyword-1; keyword-2; keyword-3; keyword-4; keyword-5. Use semicolons (;) as separator